Takeda Asia Pacific Biomedical R&D Co., Ltd.

This study is a Phase III, randomized, double-blind, placebo-controlled study sponsored by Takeda Development Center Americas, Inc. and Takeda Biopharmaceuticals Asia Pacific to evaluate the efficacy and safety of subcutaneous mezagitamab in subjects with chronic primary immune thrombocytopenia. The primary objective of the study is to evaluate the effectiveness of mezagitamab compared with placebo in achieving sustained platelet response in subjects with chronic ITP aged ≥18 years. The study is expected to screen 50 subjects in China and enroll 30 subjects.